Endocrinology, Vol 124, 1768-1773, Copyright © 1989 by Endocrine Society

ARTICLES

Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases

K Kawai, S Suzuki, S Ohashi, H Mukai, H Ohmori, Y Murayama and K Yamashita
Department of Internal Medicine, University of Tsukuba, Ibaraki-ken, Japan.

Recently, it has been demonstrated that glucagon-like peptide-1 (GLP-1)- (7-37) possesses a potent insulinotropic activity. In this paper, we compared the effects of GLP-1-(1-37) and -(7-37) and glucagon on insulin, glucagon, and somatostatin release from isolated perfused canine and rat pancreases under the perfusate condition of 5.5 mM glucose plus arginine. With canine pancreas perfusion, 1 nM GLP-1-(7- 37) was more potent in stimulating insulin and somatostatin release than was the same dose of glucagon [stimulation to 375 +/- 36% vs. 302 +/- 28% of the basal level for insulin (P less than 0.05); 724 +/- 129% vs. 311 +/- 33% of the basal level for somatostatin (P less than 0.01)]. GLP-1-(1-37) (1 nM) did not stimulate either insulin or somatostatin release. GLP-1-(7-37) (1 nM) decreased the glucagon level of the effluent perfusate to 67.2 +/- 3.4% of its basal level; but 1 nM GLP-1-(1-37) did not. Glucagon (1 nM) decreased GLP-1-like immunoreactivity to 64.0 +/- 5.2% of its basal level. With rat pancreatic perfusion, the minimal dose for stimulation of insulin release was 100 nM for GLP-1-(1-37), 0.1 nM for GLP-1-(7-37), and 1 nM for glucagon, respectively. Glucagon release was partially inhibited by 100 nM GLP-1-(1-37) and 1 and 10 nM GLP-1-(7-37). The present results indicate that 1) since GLP-1-(7-37) is released from the intestine, it might be an important incretin candidate along with gastric inhibitory peptide; and 2) the release of proglucagon-derived peptides from pancreatic A-cells is regulated by autofeedback through glucagon and GLP-1.

This article has been cited by other articles:

				I. Franklin, J. Gromada, A. Gjinovci, S. Theander, and C. B. Wollheim {beta}-Cell Secretory Products Activate {alpha}-Cell ATP-Dependent Potassium Channels to Inhibit Glucagon Release Diabetes, June 1, 2005; 54(6): 1808 - 1815. [Abstract] [Full Text] [PDF]

				R. Lopez de Maturana, A. Willshaw, A. Kuntzsch, R. Rudolph, and D. Donnelly The Isolated N-terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1 J. Biol. Chem., March 14, 2003; 278(12): 10195 - 10200. [Abstract] [Full Text] [PDF]

				L. Baggio, T. J. Kieffer, and D. J. Drucker Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice Endocrinology, October 1, 2000; 141(10): 3703 - 3709. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				G. G. Holz, IV, C. A. Leech, and J. F. Habener Activation of a cAMP-regulated Ca[IMAGE]-Signaling Pathway in Pancreatic [IMAGE]-Cells by the Insulinotropic Hormone Glucagon-like Peptide-1 J. Biol. Chem., July 28, 1995; 270(30): 17749 - 17757. [Abstract] [Full Text] [PDF]